BDX Stock Forecast & Price Target

Becton Dickinson is experiencing significant growth in key market segments, including a positive volume growth forecast for China’s volume-based procurement which is set to cover approximately 80% of its portfolio by the end of 2026, thereby bolstering its position in the growing Biosurgery market valued at nearly $400 million. Additionally, the Alaris product line has seen substantial success, recording its strongest quarter of competitive wins since its 2023 relaunch, which has contributed to an increase in category share by approximately 100 basis points. The Connected Care segment also showed promising performance, with sales reaching $1.13 billion, reflecting a year-over-year growth of 4.7% when adjusted for foreign exchange, indicating solid demand across Becton Dickinson's diverse offerings.

The financial outlook for Becton Dickinson (BDX) is negatively impacted by several factors, including a current leverage level of approximately 3x compared to management's target of 2.5x, indicating potential financial strain over the next 12-18 months. Furthermore, there are challenges from declining revenue in key segments, particularly from the Alaris business, due to tough year-over-year comparisons and weak performance in international markets like China, compounded by reduced funding in the lifesciences sector. Additionally, the company faces margin pressures from ongoing investments, tariff implications, and dilution from mergers and acquisitions, with expectations of a significant drag on overall growth in the coming fiscal years.